将既往失代偿纳入ACLF定义,加强临床管理。

IF 5.9 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY
Meiqian Hu, Jinjin Luo, Yu Wu, Jing Zhang, Peng Li, Xi Liang, Jiaojiao Xin, Dongyan Shi, Heng Yao, Shiwen Ma, Taoying Wei, Qiuzhi Wang, Xiao Wu, Yuheng Kong, Xingping Zhou, Jiaxian Chen, Hui Yang, Wen Hu, Bingqi Li, Feiyang Sun, Qingyang Ruan, Yu Chen, Jun Li, Jing Jiang
{"title":"将既往失代偿纳入ACLF定义,加强临床管理。","authors":"Meiqian Hu, Jinjin Luo, Yu Wu, Jing Zhang, Peng Li, Xi Liang, Jiaojiao Xin, Dongyan Shi, Heng Yao, Shiwen Ma, Taoying Wei, Qiuzhi Wang, Xiao Wu, Yuheng Kong, Xingping Zhou, Jiaxian Chen, Hui Yang, Wen Hu, Bingqi Li, Feiyang Sun, Qingyang Ruan, Yu Chen, Jun Li, Jing Jiang","doi":"10.1007/s12072-025-10805-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Acute-on-chronic liver failure (ACLF) is a complicated syndrome associated with high short-term mortality and reversibility. Whether the prior decompensation should be included in the definition of ACLF is controversial.</p><p><strong>Methods: </strong>A total of 532 patients with decompensation (prior or first) of chronic liver disease were retrospectively enrolled and analyzed from January 2018 to June 2023. Clinical data were used to identify the characteristics and determine prognosis.</p><p><strong>Results: </strong>Of the 532 patients, 99 patients did not meet APASL-ACLF criteria due to the existence of prior decompensation and 433 patients met the Asian Pacific Association for the Study of the Liver (APASL)-ACLF criteria. The two groups had similar characteristics including prognosis scores (Chinese Group on the Study of Severe Hepatitis B (COSSH)-ACLF II score: 7.59 vs. 7.67, p = 0.934; Chronic Liver Failure (CLIF) Consortium ACLF score: 42.90 vs. 44.81, p = 0.273), the distribution of patients with APASL ACLF research consortium score (AARC score) (5-7: 19.2%/12.0%; 8-10: 56.6%/55.0%; 11-15: 24.2%/33.0%, p > 0.05) and the 28-/90-day mortality rates (30.5%/43.2% vs. 36.3%/43.1%, p = 0.267/0.978). In all integrated ACLF patients, Receiver Operating Characteristic (ROC) curve analysis and decision curve analysis (DCA) showed that COSSH-ACLF IIs had higher prognostic efficiency and clinical net benefit than AARC score and CLIF-C ACLFs for 28-/90-day mortality.</p><p><strong>Conclusion: </strong>Prior decompensated patients exhibited clinical characteristics and high short-term mortality similar to those of first decompensated patients. The COSSH-ACLF IIs demonstrated the highest prognostic efficiency for all integrated ACLF patients. Including prior decompensation in the ACLF definition can help to simplify and improve clinical management.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":5.9000,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Integrating prior decompensation into ACLF definition to enhance clinical management.\",\"authors\":\"Meiqian Hu, Jinjin Luo, Yu Wu, Jing Zhang, Peng Li, Xi Liang, Jiaojiao Xin, Dongyan Shi, Heng Yao, Shiwen Ma, Taoying Wei, Qiuzhi Wang, Xiao Wu, Yuheng Kong, Xingping Zhou, Jiaxian Chen, Hui Yang, Wen Hu, Bingqi Li, Feiyang Sun, Qingyang Ruan, Yu Chen, Jun Li, Jing Jiang\",\"doi\":\"10.1007/s12072-025-10805-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Acute-on-chronic liver failure (ACLF) is a complicated syndrome associated with high short-term mortality and reversibility. Whether the prior decompensation should be included in the definition of ACLF is controversial.</p><p><strong>Methods: </strong>A total of 532 patients with decompensation (prior or first) of chronic liver disease were retrospectively enrolled and analyzed from January 2018 to June 2023. Clinical data were used to identify the characteristics and determine prognosis.</p><p><strong>Results: </strong>Of the 532 patients, 99 patients did not meet APASL-ACLF criteria due to the existence of prior decompensation and 433 patients met the Asian Pacific Association for the Study of the Liver (APASL)-ACLF criteria. The two groups had similar characteristics including prognosis scores (Chinese Group on the Study of Severe Hepatitis B (COSSH)-ACLF II score: 7.59 vs. 7.67, p = 0.934; Chronic Liver Failure (CLIF) Consortium ACLF score: 42.90 vs. 44.81, p = 0.273), the distribution of patients with APASL ACLF research consortium score (AARC score) (5-7: 19.2%/12.0%; 8-10: 56.6%/55.0%; 11-15: 24.2%/33.0%, p > 0.05) and the 28-/90-day mortality rates (30.5%/43.2% vs. 36.3%/43.1%, p = 0.267/0.978). In all integrated ACLF patients, Receiver Operating Characteristic (ROC) curve analysis and decision curve analysis (DCA) showed that COSSH-ACLF IIs had higher prognostic efficiency and clinical net benefit than AARC score and CLIF-C ACLFs for 28-/90-day mortality.</p><p><strong>Conclusion: </strong>Prior decompensated patients exhibited clinical characteristics and high short-term mortality similar to those of first decompensated patients. The COSSH-ACLF IIs demonstrated the highest prognostic efficiency for all integrated ACLF patients. Including prior decompensation in the ACLF definition can help to simplify and improve clinical management.</p>\",\"PeriodicalId\":12901,\"journal\":{\"name\":\"Hepatology International\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.9000,\"publicationDate\":\"2025-03-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hepatology International\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12072-025-10805-7\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatology International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12072-025-10805-7","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:急性伴慢性肝衰竭(ACLF)是一种复杂的综合征,具有较高的短期死亡率和可逆性。在ACLF的定义中是否应包括事前失偿存在争议。方法:回顾性分析2018年1月至2023年6月共532例慢性肝病失代偿(既往或首次)患者。临床资料用于识别特征和确定预后。结果:532例患者中,99例患者由于存在既往失代偿而不符合APASL-ACLF标准,433例患者符合亚太肝脏研究协会(APASL)-ACLF标准。两组预后评分相似(中国重型乙型肝炎研究组(COSSH)-ACLF II评分:7.59 vs. 7.67, p = 0.934;慢性肝衰竭(CLIF)联盟ACLF评分:42.90 vs. 44.81, p = 0.273), APASL患者ACLF研究联盟评分(AARC评分)分布(5-7:19.2%/12.0%;8 - 10: 56.6% / 55.0%;11 - 15号:24.2% / 33.0%,p > 0.05)和28 - / 90天的死亡率(30.5% vs 36.3% / 43.1% / 43.2%, p = 0.267/0.978)。在所有综合ACLF患者中,受试者工作特征(ROC)曲线分析和决策曲线分析(DCA)显示,在28天/90天死亡率方面,COSSH-ACLF评分比AARC评分和ccliff - c ACLF评分具有更高的预后效率和临床净收益。结论:既往失代偿患者与首次失代偿患者具有相似的临床特点和较高的短期死亡率。在所有综合ACLF患者中,COSSH-ACLF ii显示出最高的预后效率。将先前失代偿纳入ACLF定义有助于简化和改善临床管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Integrating prior decompensation into ACLF definition to enhance clinical management.

Background: Acute-on-chronic liver failure (ACLF) is a complicated syndrome associated with high short-term mortality and reversibility. Whether the prior decompensation should be included in the definition of ACLF is controversial.

Methods: A total of 532 patients with decompensation (prior or first) of chronic liver disease were retrospectively enrolled and analyzed from January 2018 to June 2023. Clinical data were used to identify the characteristics and determine prognosis.

Results: Of the 532 patients, 99 patients did not meet APASL-ACLF criteria due to the existence of prior decompensation and 433 patients met the Asian Pacific Association for the Study of the Liver (APASL)-ACLF criteria. The two groups had similar characteristics including prognosis scores (Chinese Group on the Study of Severe Hepatitis B (COSSH)-ACLF II score: 7.59 vs. 7.67, p = 0.934; Chronic Liver Failure (CLIF) Consortium ACLF score: 42.90 vs. 44.81, p = 0.273), the distribution of patients with APASL ACLF research consortium score (AARC score) (5-7: 19.2%/12.0%; 8-10: 56.6%/55.0%; 11-15: 24.2%/33.0%, p > 0.05) and the 28-/90-day mortality rates (30.5%/43.2% vs. 36.3%/43.1%, p = 0.267/0.978). In all integrated ACLF patients, Receiver Operating Characteristic (ROC) curve analysis and decision curve analysis (DCA) showed that COSSH-ACLF IIs had higher prognostic efficiency and clinical net benefit than AARC score and CLIF-C ACLFs for 28-/90-day mortality.

Conclusion: Prior decompensated patients exhibited clinical characteristics and high short-term mortality similar to those of first decompensated patients. The COSSH-ACLF IIs demonstrated the highest prognostic efficiency for all integrated ACLF patients. Including prior decompensation in the ACLF definition can help to simplify and improve clinical management.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Hepatology International
Hepatology International 医学-胃肠肝病学
CiteScore
10.90
自引率
3.00%
发文量
167
审稿时长
6-12 weeks
期刊介绍: Hepatology International is the official journal of the Asian Pacific Association for the Study of the Liver (APASL). This is a peer-reviewed journal featuring articles written by clinicians, clinical researchers and basic scientists is dedicated to research and patient care issues in hepatology. This journal will focus mainly on new and emerging technologies, cutting-edge science and advances in liver and biliary disorders. Types of articles published: -Original Research Articles related to clinical care and basic research -Review Articles -Consensus guidelines for diagnosis and treatment -Clinical cases, images -Selected Author Summaries -Video Submissions
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信